RxDoctor Payments Data

Christopher Harden, MD

Critical Care Medicine · Gainesville, FLNPI 1306282124

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,850 of the $5,909 with a category attached, or 65.2%. United Therapeutics Corporation accounts for 90.1% of it on its own, with 1 other manufacturer making up the rest. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,909in general payments, 2019–2025

Across 17 payments — averaging $347.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$5K
  • Boehringer Ingelheim$587
$708,123in research payments, 2019–2025

Across 105 payments — averaging $6744.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$404K
  • E.r. Squibb & Sons, L.L.C.$275K
  • Boehringer Ingelheim International GmbH$27K
  • GSK$1K
  • Novartis$33

What the payments were for

  • Consulting fees$3,85065%
  • Travel & lodging$1,41224%
  • Food & beverage$64611%

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,909 in reported general payments places this provider in the 90th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$99,955
Medicare patients
305
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate123$1,624,459
Pirfenidone16$35,498
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,438
Breo ElliptaFluticasone/Vilanterol27$12,162
Mycophenolate Mofetil68$9,455
AsmanexMometasone Furoate12$1,876
Albuterol Sulfate HfaAlbuterol Sulfate34$994
Ventolin HfaAlbuterol Sulfate18$982
Prednisone39$353
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim31$255
Fluticasone Propionate11$181
MethotrexateMethotrexate Sodium14$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$587$1,624,459123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →